Hossain Sanghi, Sforza Maggi

ABSTRACT

Background: Neonatal hyperbilirubinemia remains one of the most frequent metabolic conditions encountered in the early neonatal period, with potential progression to bilirubin encephalopathy if not identified and managed promptly. From a pharmacotherapeutic standpoint, serum albumin plays a critical role in modulating bilirubin toxicity through high-affinity binding of unconjugated bilirubin, thereby reducing the free bilirubin fraction available for neurotoxic interactions. Consequently, cord serum albumin concentration at birth has been proposed as a clinically relevant biomarker to stratify the risk of hyperbilirubinemia and guide early therapeutic interventions. Aim: To evaluate the pharmacotherapeutic relevance of cord serum albumin as a predictive biomarker for neonatal hyperbilirubinemia and to analyze bilirubin kinetics using sequential transcutaneous bilirubin (TCB) monitoring